Cholesterol & weight plan — second-opinion prep

A single evolocumab (Repatha) dose lowers LDL ~55–60% and has an effective half-life of 11–17 days — so a lab two weeks later reflects atorvastatin + ezetimibe plus residual PCSK9 effect (FOURIER). Your true LDL on the oral pills alone has never been measured; stopping the drug lets it drift back up.

If you're on Repatha for established cardiovascular disease (ASCVD), familial hypercholesterolemia, or very-high-risk status, your goal may be closer to LDL <55 / Non-HDL <85 — at 65 / 88 you'd be just above it. If not, <70 may be the relevant target, and 65 is at goal. So the real second-opinion question is: what risk category are we treating? (ESC/EAS 2019 · AHA/ACC 2018).

Nausea with evolocumab runs ~1–2% — at or below placebo; its typical effects are injection-site reactions and cold symptoms, so the nausea→Repatha link is shaky (FOURIER / Repatha label). And if you want to avoid the injection but still need lower LDL, bempedoic acid is oral, non-statin, and the only oral option besides ezetimibe with cardiovascular-outcome data (CLEAR Outcomes).

Mounjaro is FDA-approved for type-2 diabetes; Zepbound is the same molecule (tirzepatide) approved for weight loss — so unless you have diabetes, Mounjaro for weight loss is off-label, and Zepbound is the indicated product (it also affects coverage). Mean weight loss is ~15–21% (SURMOUNT-1), so −100 lb is realistic only from a very high starting weight. And the irony: you're leaving a drug over nausea to start one whose #1 side effect is nausea (25–29%).

TG 151 + HDL 30 + obesity is the classic atherogenic-dyslipidemia pattern of insulin resistance / metabolic syndrome — you already meet 2 of 5 criteria before counting waist, blood pressure, or glucose (2009 Harmonizing definition). Treating the root (weight, insulin sensitivity) moves triglycerides, HDL, and LDL particles together — exactly what real weight loss does (Look AHEAD).

The triglyceride half is well-supported (weight loss + tirzepatide reliably lower TG). But raising HDL with a drug has never improved cardiovascular outcomes — the niacin trials failed outright (AIM-HIGH, HPS2-THRIVE). HDL 30 is a risk marker, not a number to drug upward; weight loss is the right lever. And tirzepatide does little for LDL, so it does not address the LDL / PCSK9 question.

ApoB counts atherogenic particles directly and beats LDL-C when triglycerides are up — your TG 151 means LDL 65 may under-state your true particle burden (NLA ApoB consensus). Lp(a) is a once-in-a-lifetime genetic test; high Lp(a) is a common reason for aggressive therapy — and the PCSK9 you're stopping lowers Lp(a) ~27%, so if it's high, dropping the drug is the wrong move (EAS Lp(a) consensus & FOURIER). Triple therapy also raises the question of familial hypercholesterolemia; a TSH rules out the commonest reversible cause. Not innocuous — this sharpens the picture, it doesn't alarm.

Lowering LDL reduces but doesn't erase risk — even at goal, an inflamed plaque can rupture and clot. Targeting inflammation cuts events on top of LDL (CANTOS, colchicine), and hs-CRP detects it. Blood pressure is the cheapest, highest-yield, currently-unmeasured lever — far more valuable than chasing HDL. (A CAC / calcium scan is most useful when your risk is uncertain — and here it may be: if you're on these drugs for documented disease or familial hypercholesterolemia, a CAC adds little; but if it's mainly for a high LDL number without documented disease, a CAC could reveal whether this aggressive treatment is even warranted. Its value hinges on the one fact we don't yet have — why you're on these drugs.)

Only prescription icosapent ethyl (pure EPA) has a positive outcome trial — REDUCE-IT cut events ~25% in statin patients with TG 135–499 (your 151 qualifies; REDUCE-IT). But EPA+DHA (STRENGTH) was null, and OTC fish oil has no outcome benefit (and unregulated potency). So "omega-3 helps" applies only to the prescription pure-EPA form — not the fish oil on the shelf. Your TG 151 is at the low end and may normalize with weight loss first — an "if it stays up" move.

⚖ Where the evidence fights: these two omega-3 trials directly disagree — REDUCE-IT (pure EPA) cut events, STRENGTH (EPA+DHA) showed nothing. And it isn't fully settled: critics argue REDUCE-IT's mineral-oil placebo may have raised events in the control group, inflating the apparent benefit. So "prescription EPA works" is the leading read — but it's a real, unresolved fight, not settled fact.

Your high-TG / low-HDL pattern is carbohydrate-driven hepatic VLDL overproduction, not dietary cholesterol (de novo lipogenesis) — so cutting glycemic load lowers triglycerides. Low-carb beats low-fat on the TG/HDL pattern (Bazzano −14 TG, +7 HDL), though not always on weight. But the trade-off: low-carb / keto reliably raises LDL-C (62-RCT meta: +8.5 mg/dL) — a problem since you're already fighting LDL — so track ApoB, not just LDL-C. The one diet with hard cardiovascular-outcome data is the Mediterranean / lower-GL pattern (PREDIMED), which cuts TG via weight + carb quality without the saturated-fat LDL surge. For your insulin-resistant, high-TG profile, a lower-glycemic-load version of it is the natural refinement — though head-to-head that mainly improves after-meal triglycerides, not the fasting numbers or hard outcomes (MEDGI-Carb).

⚖ The trade-off: keto helps the axes you care about — triglycerides, HDL, blood sugar, weight — but can raise the LDL you're treating hardest. A lower-glycemic-load Mediterranean pattern captures most of the metabolic win without the LDL surge — the safer bet for your profile.

From the head-to-head trials: they all work for the metabolic root — but none is a weight magic bullet. For insulin resistance, weight loss + HIIT + low-carb + metformin are all real levers (HIIT shines per-time and improves insulin sensitivity even without weight change — Obes Rev meta). For weight magnitude, the GLP/GIP drug out-classes everything (~15–21%); among lifestyle the options are similar — low-carb ≈ low-fat, HIIT ≈ moderate exercise, fasting ≈ calorie restriction — so adherence decides it (named-diet network meta-analyses).

⚖ Take-home: for your insulin-resistance root, several real levers — HIIT is the standout per hour, with low-carb + metformin helping too. For weight, the drug does the heavy lifting and "the best diet is the one you stick to." One catch (ties to Flag 10): low-carb is worse for your LDL at equal weight loss — so favour a Mediterranean / lower-GL pattern.

⚖ Counter-intuitive — and relevant to you: metformin can blunt exercise. For insulin sensitivity and fitness the two are antagonistic, not additive — so if you're counting on exercise to fix insulin resistance, the metformin may be working against it (Konopka · Sharoff · Malin). (For glycemic control / diabetes prevention, both still help — the antagonism is specific to the insulin-sensitivity / fitness adaptations.)

"Lower is better" — deeper LDL lowering means fewer events with no clear harm floor, so keeping high-intensity at LDL 65 is defensible (CTT); the real question is dose-vs-tolerability, not stopping. Muscle aches are largely nocebo in blinded trials (SAMSON). One honest nuance for you: high-intensity statins cause a small, real increase in new-onset diabetes (meta-analysis OR 1.09) — especially relevant since you're already insulin-resistant. For genuinely high-risk patients, guidelines judge the heart benefit to outweigh this small diabetes risk; but whether it does for you depends on your actual CV risk (which we don't yet know) and is a real trade-off to weigh — not a settled call — given diabetes's own severe complications. Separately, the statin already lowers your triglycerides ~10–30%.

The goal of the lipid drugs isn't a lower LDL number — it's a lower absolute chance of a heart attack over years, and that benefit equals the relative reduction times your baseline risk (CTT). So at LDL 65 the further 65→55 shave buys little in absolute terms — and whether the aggressive drugs are worth it at all depends on a risk tier we don't actually have (the #1 missing fact). Meanwhile the weight axis is not cosmetic — losing weight cut major cardiovascular events ~20% (SELECT) — and diabetes is the other major risk — its complications (eyes, kidneys, limbs) scaling with blood sugar (UKPDS). But the weight drug is a chronic dependency — stop it and most of the weight returns (STEP-1 extension), and ~25% of the loss is muscle — so lifestyle has to be the foundation, and lifestyle alone is powerful for the thing that matters most here (it cut diabetes 58%).

⚖ The reframe: the highest-value move for both your quality of life now and your risk later is most likely the metabolic root (weight, insulin resistance, avoiding diabetes) — not the LDL fine-tuning. And whether you even need the aggressive lipid drugs hinges on the one question no one has answered: why are you on them?

Your sex was never stated — and it matters. "Low HDL" is <40 for men but <50 for women (MetS criteria), so HDL 30 is very low either way — ~20 below the female cutoff. If you're a woman: menopause shifts lipids the wrong way (TG/ApoB up, HDL down) and adds insulin resistance + visceral fat (SWAN), and diabetes erases more of women's heart protection (44% higher excess risk than men). Worth checking the hormonal drivers — thyroid (the TSH already flagged), PCOS, and Lp(a) (rises after menopause). Statins themselves work equally in both sexes (CTT), though women report more muscle symptoms.

⚖ The applicability caveat: most of these trials report pooled (both-sex) results, so applying one hazard ratio to your sex carries uncertainty. The statin and diabetes-CV evidence is sex-stratified; the weight-drug magnitude is not — so "women lose more on these drugs" is not established (one real-world split actually found men lost more). And your sex isn't even on the chart yet.